Head-to-head evidence
HS-20137 vs picankibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
HS-20137
Developed by Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06844799 (registry estimate)
picankibart
Developed by Innovent Biologics
NCT05645627 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 500 participants. The sponsor reports that picankibart met its co-primary endpoints, with 80.3% of picankibart patients reaching PASI90 (at least 90% skin clearance) at week 16, compared with 2.0% of placebo patients, a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20137's landscape · picankibart's landscape